The bivalent and quadrivalent cervical cancer vaccines can be given to patients who are 28 years old. The bivalent vaccine mainly contains 16 and 18 viruses, although it can prevent few types of diseases, it is more targeted and has a very good effect on cervical cancer prevention. 99% of cervical cancer tissues are found to be infected with high-risk HPV viruses, and about 70% of them are related to 16 and 18. The quadrivalent vaccine mainly contains the prevention of 6, 11, 16 and 18 of these viruses, which can prevent cervical cancer and at the same time, can play a role in preventing the occurrence of genital condyloma in women, so the range of diseases that can be prevented is relatively wide. Regardless of whether a patient receives the bivalent or quadrivalent cervical cancer vaccine, a cervical screening test is required before the vaccination to determine whether the patient is already infected with the HPV virus.